Public Companies
Awakn Life Sciences’ Revenue up 534% in 2022, AUD Treatment Advances
The firm has made meaningful strides in its early clinical runway as it gears up for government-funded studies.
The post Awakn Life Sciences’ Revenue…
Toronto-based Awakn Life Sciences Corp. (OTC: AWKNF), a biotech company focused on addiction treatments, reported a heft 534% rise in annual revenue for the fiscal year ended Jan. 31, which they attribute to the strong performance of their clinics.
The company pulled in $1.5 million in annual revenue, a 534% increase year-on-year, with $471,813 in the fourth quarter, a 131% increase sequentially. Net loss for the year was $9.7 million, and improvement versus $16.5 million in 2021.
Awakn had around $550,866 in cash at the end of the period.
“Our clinics delivered strong revenue growth … and looking forward to the current fiscal year, we are targeting a further increase in revenue from our clinics and partnerships,” CEO Anthony Tennyson said in a statement.
Awakn’s main program, AWKN-P001, which aims to treat severe alcohol use disorder (AUD), is moving into phase III. The U.K. government will cover most of the trial costs, leaving Awakn to contribute only $1.25 million.
Additionally, the company is partnering with a European pharmaceutical firm to study the potential of repurposing (S)-ketamine for addiction treatment. Awakn is also working with Catalent on a study of MDMA, using Catalent’s proprietary oral disintegrating tablet technology, which could potentially shorten therapy sessions.
Recently, Awakn received an Innovation Passport – a licensing pathway for pre-clinical ventures – from the U.K. Medicines and Healthcare Products Regulatory Agency for its ketamine-assisted therapy for severe AUD. The company also signed a collaboration agreement with the University of Exeter for an upcoming phase III trial.
The post Awakn Life Sciences’ Revenue up 534% in 2022, AUD Treatment Advances appeared first on Green Market Report.
mdma ketamine therapy otc awakn life sciences awakn
What marijuana reclassification could mean for health treatments
MindBio Therapeutics Announces Landmark Women’s Health CNS Drug Trials
Reunion Neuroscience Inc. Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo Holdings
Reunion Neuroscience Inc. Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo Holdings
MindBio Therapeutics Announces Landmark Women’s Health CNS Drug Trials
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
-
Psychedelics1 week agoRevive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Psychedelics1 week agoAlgernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Law & Regulation1 week agoTryp Therapeutics merger with Exopharm approved by shareholders
-
Psilocybin1 week agoPassover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week agoatai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Psychedelics1 week agoSilo Pharma Announces Positive Results for Intranasal PTSD Treatment
-
Psilocybin1 week agoPsilocybin and Meditation: Unlocking the Potential for Enhancing Insightfulness
-
Law & Regulation1 week ago
Tryp Therapeutics, Exopharm merger approved by shareholders